Given that the neomorphic activity of IDH promotes oncogenesis in IDH-mutant GBM cells through the production of oncometabolite D-2-HG, IDH inhibitors such as ivosidenib and vorasidenib have also been developed to block the downstream production of D-2-HG. The gene discussed is IDH2; the disease is glioblastoma.